Convergent MurJ flippase inhibition by phage lysis proteins.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41741639.
- Also identified by DOI 10.1038/s41586-026-10163-w.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Antimicrobial drug resistance poses a global health challenge that necessitates the identification of new druggable targets<sup>1-3</sup>. The essential lipid II flippase MurJ is a promising yet underexplored antimicrobial target in bacterial cell wall biosynthesis<sup>4-7</sup>. The only known inhibitors of Gram-negative (diderm) MurJ are the single-gene lysis proteins (Sgls) from the lytic single-strand RNA phages M (Sgl<sup>M</sup>) and PP7 (Sgl<sup>PP7</sup>)<sup>8,9</sup>. Sgl<sup>M</sup> and Sgl<sup>PP7</sup> have distinct evolutionary origins and share no sequence similarity. Here we describe a common mechanism of MurJ inhibition by these phage-encoded Sgls. We determined the structures of MurJ-bound Sgl<sup>M</sup> and Sgl<sup>PP7</sup> and discovered a third distinct MurJ-targeting Sgl from the predicted phage Changjiang3 (Sgl<sup>CJ3</sup>) that we also characterized structurally. Our findings demonstrate that all three Sgls evolved convergently to trap MurJ in a periplasm-open conformation through a common MurJ interface, revealing a pathway for drug design.